Write in a clean editor, then format for Immunotherapy Advances in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Immunotherapy Advances is a peer-reviewed journal published by Oxford University Press, covering Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune Cell Function and Interaction.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Immunotherapy Advances, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — Immunotherapy Advances has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Immunotherapy and Immune Responses CAR-T cell therapy research Immune Cell Function and Interaction Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology |
| ISSN | 2732-4303 |
| Citation impact (2-yr) | 2.79 |
| h-index | 23 |
| i10-index | 55 |
| Total citations | 1,719 |
| Article processing charge | $2,575 |
| Open access | Yes |
| Top institutions publishing here | University of Oxford |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the development of new therapeutic approaches a topic of ongoing research. Chimeric antigen receptor (CAR) cells are engineered immune cells that are programmed to specifically…
Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the…
Immunotherapies are disease management strategies that target or manipulate components of the immune system. Infectious diseases pose a significant threat to human health as evidenced by countries continuing to grapple with several emerging and re-emerging diseases, the most recent global health threat being the SARS-CoV2 pandemic. As such, various immunotherapeutic approaches are increasingly being investigated…
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known for its positive safety profile) was conjugated to ultrasmall gold nanoparticles…
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several advanced malignancies leading to durable remission in a subset of patients. Their rapidly expanding use has led to an increased frequency of immune-related adverse events (irAEs). The pathogenesis of irAEs is poorly understood but may involve aberrant activation of T cells leading to inflammatory cytokine…
